市場調查報告書
商品編碼
1426873
全球獸醫疼痛管理市場:~2030 年Veterinary Pain Management Market Forecast to 2030 |
在預測期內,全球獸醫疼痛管理市場規模預計將穩定維持在 6.44% 的複合年增長率。 動物疾病的流行、伴侶動物繁殖率的上升以及寵物數量的增加等因素正在推動市場的成長。
按地區劃分,北美市場在 2022 年佔據最大份額。 這是由於該地區寵物數量的增加和神經系統疾病的增加。 此外,歐洲市場是世界第二大市場,由於傳染病的傳播,人們對疼痛管理產品的興趣日益濃厚。 亞太地區的成長得益於中國、印度和韓國等快速發展經濟體的存在。 該地區為進入者提供了許多寶貴的發展機會。 寵物選擇的擴大和伴侶動物數量的增加正在推動市場的發展。
本報告調查了全球動物疼痛管理市場,提供了市場的定義和概述,分析了市場成長的各種影響因素、市場規模的趨勢和預測、各個細分市場和地區的細分,總結了競爭環境,主要公司簡介等
Global Veterinary Pain Management market is projected to register a healthy CAGR of 6.44% during the reviewt period. Developing commonness of painful and fiery illnesses in creatures and ascend in sidekick creature proprietorship and huge pet populace are driving market development.
The ascent in sidekick creature possession and enormous animals' populace, ascend in pet protection with a flood in creature wellbeing consumption, and developing predominance of creature illnesses are supposed to drive the development of the worldwide veterinary pain management market.
The rising number of pet people across the globe is supposed to help market development over the forecast period. For example, as per the American Culture for the Anticipation of Mercilessness to Creatures (ASPCA), around 6.5 million sidekick creatures enter the US creature shields cross country every year. Besides, as expressed by the American Pet Items Affiliation 2015 to 2016 (APPA) study, roughly 44% of all families in the US had a canine, and 35% had a feline.
Devices and drugs are included in the product-based segmentation of the worldwide veterinary pain treatment market. The market has been further divided into categories based on pharmaceuticals, including opioids, local anesthetics, nonsteroidal anti-inflammatory drugs (NSAIDs), and others. The NSAIDs category has been further divided into categories such as etodolac, meloxicam, and others.
Joint pain, postoperative pain, cancer, and other conditions are among the applications used to segment the worldwide veterinary pain management market.
Companion and farm animals are the two animal types used to segment the worldwide veterinarian pain management market. Dogs, cats, horses, and other animals have been further subdivided under companion animals. The market has been further subdivided into cattle, pigs, poultry, and other livestock-based animals.
The global veterinary pain management market segmentation is based on a distribution channel that includes veterinary hospitals & clinics, pharmacies, and online pharmacies.
Regional Insights
The North America clear aligners market represented the biggest market share in 2022. This is because of the rising pet populace and the rising number of neurological sicknesses in the region. Besides, the presence of numerous observable players like Zoetis (New Jersey, US), Merck and Co., Inc. (New Jersey, US), and Assisi Creature Wellbeing (New Mexico, US) in this region is the significant driving variable of the market in the North America.
Europe Veterinary Pain Management market represents the second-largest market owing to the rising pervasiveness of contagious creature sicknesses and expanded center around the wellbeing and prosperity of creatures is driving the interest in pain management items.
The Asia-Pacific Veterinary Pain Management market expansion is attributed to the presence of quickly creating economies of China, India, and South Korea. The region gives numerous valuable chances to market players to develop. The expanded pet selections and development in the number of inhabitants in sidekick creatures is supposed to drive the market development.
The Middle East and Africa region has less monetary turns of events and very low pay because of which the region represents the least market share yet is supposed to develop with the to further developing veterinary medical care offices and extension of the working-class populace in these regions.
Major Players
Companies such as Boehringer Ingelheim (Ingelheim am Rhein, Germany), Vetoquinol (Lure, France), Ceva Animal Health, LLC (Libourne, France), Dechra Pharmaceuticals PLC (Northwich, UK), Zoetis (New Jersey, US), Merck & Co., Inc. (New Jersey, US), Assisi Animal Health(New Mexico, US), Eltech K-Laser (Treviso, Italy), Chanelle Pharma (Galway, Ireland), and Elanco (Indiana, US).
TABLE OF CONTENTS